Resumen
Background: The presence of smaller low-density lipoproteins (LDL) has been associated with atherosclerosis risk, and the insulin resistance (IR) underlying the metabolic syndrome (MetS). In addition, some research has supported the association of very low-, low- and high-density lipoprotein (VLDL HDL) particle diameters with components of the metabolic syndrome (MetS), although this has been the focus of less research. We aimed to explore the relationship of VLDL, LDL and HDL diameters to MetS and its features, and by clustering individuals by their diameters of VLDL, LDL and HDL particles, to capture information across all three fractions of lipoprotein into a unified phenotype. Methods. We used nuclear magnetic resonance spectroscopy measurements on fasting plasma samples from a general population sample of 1,036 adults (mean ± SD, 48.8 ± 16.2 y of age). Using latent class analysis, the sample was grouped by the diameter of their fasting lipoproteins, and mixed effects models tested whether the distribution of MetS components varied across the groups. Results: Eight discrete groups were identified. Two groups (N = 251) were enriched with individuals meeting criteria for the MetS, and were characterized by the smallest LDL/HDL diameters. One of those two groups, one was additionally distinguished by large VLDL, and had significantly higher blood pressure, fasting glucose, triglycerides, and waist circumference (WC; P <.001). However, large VLDL, in the absence of small LDL and HDL particles, did not associate with MetS features. These associations held after additionally controlling for VLDL, LDL and HDL particle concentrations. Conclusions: While small LDL diameters remain associated with IR and the MetS, the occurrence of these in conjunction with a shift to overall larger VLDL diameter may identify those with the highest fasting glucose, TG and WC within the MetS. If replicated, the association of this phenotype with more severe IR-features indicated that it may contribute to identifying of those most at risk for incident type II diabetes and cardiometabolic disease.
| Idioma original | English |
|---|---|
| Número de artículo | 237 |
| Publicación | Lipids in Health and Disease |
| Volumen | 10 |
| DOI | |
| Estado | Published - 2011 |
Nota bibliográfica
Funding Information:We are grateful to the staff of the GOLDN study for the assistance in data collection and management. Sources of funding This study was funded by NHLBI grant number U01HL072524. Financial disclosures: None to declare. Disclosure: All authors declare that they have no conflicts of interests.
Financiación
We are grateful to the staff of the GOLDN study for the assistance in data collection and management. Sources of funding This study was funded by NHLBI grant number U01HL072524. Financial disclosures: None to declare. Disclosure: All authors declare that they have no conflicts of interests.
| Financiadores | Número del financiador |
|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | U01HL072524 |
| National Institute of Diabetes and Digestive and Kidney Diseases | R01DK083562 |
ODS de las Naciones Unidas
Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible
-
Good health and well being
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Endocrinology
- Clinical Biochemistry
- Biochemistry, medical
Huella
Profundice en los temas de investigación de 'A clustering analysis of lipoprotein diameters in the metabolic syndrome'. En conjunto forman una huella única.Citar esto
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver